The Developer's Checklist For Evaluating In-Vivo CAR-T Manufacturing Partners

In vivo CAR-T therapies could help developers overcome some of the manufacturing complexity associated with ex vivo approaches, but eliminating cell extraction, engineering, and reinfusion does not eliminate development risk. Success requires careful coordination across delivery system design, formulation, analytics, regulatory strategy, and cGMP manufacturing.

Choosing a development partner without the right capabilities can create downstream challenges as programs move from the laboratory toward clinical and commercial production. Sponsors must account for modality-specific considerations across viral vectors and lipid nanoparticles. They also need the flexibility to adapt as clinical data emerge without sacrificing quality, compliance, or timelines.

So, what separates a strategic development partner from a transactional vendor? The answer lies in capabilities that extend beyond individual manufacturing steps. Sponsors should evaluate prospective partners for multimodal expertise, formulation and analytical capabilities, regulatory experience, scalable manufacturing infrastructure, and the ability to support development from early stages through GMP manufacturing.

Explore the complete article to discover the questions sponsors should ask when evaluating in vivo CAR-T development and manufacturing partners.